SB8: A Bevacizumab Biosimilar

SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy vol...

Descripción completa

Detalles Bibliográficos
Autor principal: Syed, Yahiya Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Adis Biosimilar Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733936/
https://www.ncbi.nlm.nih.gov/pubmed/33206282
http://dx.doi.org/10.1007/s11523-020-00776-0
_version_ 1783622365303799808
author Syed, Yahiya Y.
author_facet Syed, Yahiya Y.
author_sort Syed, Yahiya Y.
collection PubMed
description SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles.
format Online
Article
Text
id pubmed-7733936
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77339362020-12-17 SB8: A Bevacizumab Biosimilar Syed, Yahiya Y. Target Oncol Adis Biosimilar Brief SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles. Springer International Publishing 2020-11-18 2020 /pmc/articles/PMC7733936/ /pubmed/33206282 http://dx.doi.org/10.1007/s11523-020-00776-0 Text en © Springer Nature 2020, corrected publication 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Adis Biosimilar Brief
Syed, Yahiya Y.
SB8: A Bevacizumab Biosimilar
title SB8: A Bevacizumab Biosimilar
title_full SB8: A Bevacizumab Biosimilar
title_fullStr SB8: A Bevacizumab Biosimilar
title_full_unstemmed SB8: A Bevacizumab Biosimilar
title_short SB8: A Bevacizumab Biosimilar
title_sort sb8: a bevacizumab biosimilar
topic Adis Biosimilar Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733936/
https://www.ncbi.nlm.nih.gov/pubmed/33206282
http://dx.doi.org/10.1007/s11523-020-00776-0
work_keys_str_mv AT syedyahiyay sb8abevacizumabbiosimilar

Ejemplares similares